Introduction
Macrophages are an important component of the inflammatory response and their Fcey receptors are significant in their function. Factor XII (Hageman factor) is an 80-kD proenzyme present in blood, that upon activation is responsible for initiating the intrinsic pathway of blood coagulation and is implicated in the pathophysiology of inflammation, kinin formation, complement activation, and fibrinolysis (1) . Although Factor XII has been shown to activate granulocytes (2), an interaction between Factor XII and macrophages is unknown. The (100 U/ml), streptomycin (100 gg/ml), gentamicin (20 ,ug/ml), and 2 mM L-glutamine. EDTA buffer consisted of Dulbecco's PBS containing 0.1% gelatin, 0.01 M EDTA, and 0.1% sodium azide.
Hageman factor (Factor XII) was purified as previously described using zinc chelate Sepharose and gel filtration chromatography (7) or monoclonal antibody immunoaffinity column chromatography (6) . Factor XII was determined to be homogeneous with Mr 80 kD using SDS PAGE and had specific activities of60-90 U/mg (6, 7) , where 1 U is the amount of Factor XII present in 1 ml of a pool of plasma from normal individuals. Factor XII was converted to Factor XIIa by purified plasma kallikrein and the enzymes were separated by ion exchange chromatography as previously described (8) . Factor XIIa concentrations of these fractions were determined from the difference in the value of coagulant activity and the amidolytic activity of the enzyme against the peptide substrate, H-D-Pro-Phe-Arg-pNA (S-2302), and confirmed by scanning on SDS PAGE. Coagulant activity was measured by a modification of the activated partial thromboplastin time (9), using Factor XII-deficient plasma. The amidolytic assay was performed using S-2302 (10) with modifications (8) . Most Factor XIIa fractions used in these studies contained some zymogen Factor XII and Factor XIIf. However, the amount of Factor XIIa in all preparations used was at least 50% and was determined for each preparation used. Factor XIIf was purified to homogeneity (30 kD) by incubating the activation mixtures with 2 mg/ml kaolin in 0.01 M Tris, pH 8.0, and removing the kaolin by sedimentation. Kaolin under these conditions binds Factor XII and Factor XIIa, but not Factor XIIf, leaving Factor XIIf in homogeneous form in the supernatant. Factor XIIf activity was determined by S-2302 amidolytic activity, since it has virtually no coagulant activity.
Corn trypsin inhibitor, a specific reversible inhibitor ofFactor XIIa and Factor XIIf, first described by Hojima et al. (11), was a generous gift from Dr. E. Kirby of Temple University (Philadelphia, PA), and was purified from corn as described (12) .
The catalytic activity of Factor XIIa was inhibited by pretreating Factor XIIa just before the experiment with either corn trypsin inhibitor or DFP. DFP was added to Factor XIIa for a final DFP concentration of3.6 mM and incubated 30 min at 230C. Factor XIIa activity was then examined for amidolytic activity using S-2302 and no hydrolysis was detected.
The Factor XIIa effect was also examined in the presence of serum, using FCS which contains low amounts of IgG. Monocytes were preincubated with Factor XIIa in the presence or absence of either 10 or 50% FCS before the enumeration of monocyte IgG binding sites. Preparation ofmonocytes. We used a method to isolate monocytes in suspension based upon their adherence to serum-treated flasks and their ability to be dislodged in the cold by indirect mechanical means (13, 14) . Whole blood anticoagulated with sodium heparin was obtained from normal donors and the mononuclear cells isolated by centrifugation on a Ficoll-Hypaque gradient (13) . The mononuclear cells were washed once and suspended in RPMI complete medium. (15) with BSA as the standard. In selected experiments, human IgG was prepared by ammonium sulfate precipitation and gel filtration chromatography in order to obtain large amounts of IgG (13) . IgG fractionated as IgG monomer when analyzed by Sephadex G-200 chromatography and was found to contain only IgG when assessed by double immunodiffusion, immunoelectrophoresis, and polyacylamide disk-gel electrophoresis (13).
The isolated IgG was labeled with 1251I (New England Nuclear, Boston, MA) using chloramine-T followed by Sephadex G-50 chromatography as previously described (13, 14) and stored at 4VC until use. Specific activity of the final preparation was 0.16 uCi/gg of protein. Immediately before each assay, the IgG was centrifuged in an airfuge (Beckman Instruments, Inc., Palo Alto, CA) at 100,000 g for 15 min.
Monocytes were exposed to Factor XII, Factor XIIf, Factor XIIa, and inactivated forms of Factor XIIa in EDTA buffer for at least 30 min at 370C before determination of IgG binding. Equilibrium binding of '251-IgG monomer to monocytes was performed as previously published (13, 14) . Enzyme-treated or control monocytes (1 X 106) were incubated with one concentration or increasing concentrations of '251-IgG in EDTA buffer (total volume 0.5 ml) at 370C for 30 min to reach equilibrium conditions. '251I-IgG input per experimental tube in the figures refers to '25I-gG per 0.5 ml of total volume. The amount of cell-associated and unbound 125I-IgG was determined by rapidly sedimenting the cells through a layer (0.5 ml) of silicone oil mixture (25 ml methyl silicone + 80 ml biphenyl silicone), and the radioactivity in the cellular pellets was quantitated in a gamma counter. Nonspecific binding was defined as the cell-associated radioactivity in the presence of 100-fold excess of unlabeled IgG. Unlabeled IgG at this concentration displaced > 70% of the total cell-associated counts. Specific binding was analyzed by Scatchard plots as previously described (13, 14) . The We studied the effect of Factor XIIa on the monocyte C3 receptors CR1 and CR3, the receptors for C3b and iC3b, respectively, using two monoclonal antibodies. Factor XIIa did not diminish CR1 or CR3 expression as assessed by flow cytometry with these monoclonal antibodies. Monocytes preincubated with Factor XIIa expressed a mean fluorescence intensity of 28±5 and 32±15 (n = 5) with anti-CRl and anti-CR3, respectively, compared with a mean fluorescence intensity of 28±6 and 31 ± 12 in the absence of Factor XIIa.
We further examined the effect of Factors XIIf and XII on the number of IgG binding sites expressed. We incubated 0.09 MM of Factor XIIf or XII with monocytes at 370C for 30 min and then determined the equilibrium binding of monomeric IgG over a wide concentration of IgG from 0.05 Ag/ml to 2.0 ug/ml (Table I) . In contrast to Factor XIIa, which inhibited the specific binding of IgG to monocytes by 46% in this experiment, XIIfdid not affect the number ofbinding sites expressed for monomeric IgG. To determine whether activation of Factor XII is necessary to allow Factor XIIa to alter the expression of monocyte binding sites for monomeric IgG, we studied the effects of zymogen (precursor) Factor XII ( Table I) . We observed that Factor XII (0.09 MM) failed to alter the number and affinity ofbinding sites for monomeric IgG on monocytes, while in a parallel experiment, Factor XIIa inhibited the specific binding of monomeric IgG by 34% (Table I) .
The proteolytic and amidolytic activity of Factor XIIa is inhibited specifically by corn trypsin inhibitor in a tight binding reversible interaction (1 1). To examine whether catalytically active Factor XIIa is responsible for this effect on the monocyte binding sites for IgG, Factor XIIa was preincubated with corn trypsin inhibitor. Corn trypsin inhibitor completely inhibited the coagulant activity and the amidolytic activity of Factor XIIa (data not shown). There was no change in the ability of corn trypsin inhibitor inactivated Factor XIIa to reduce the expression ofmonocyte IgG binding sites (Table II) .
Corn trypsin inhibitor is a polypeptide of Mr = 14 kD ( 11) and a reversible inhibitor. Thus, its failure to alter the effect of Factor XIIa could be due to steric interference or dissociation of Factor XIIa from the enzyme-inhibitor complex. Therefore, we used as an inhibitor DFP, which is a small (184 D) irreversible alkylator ofthe active site serine in Factor XIIa. Similar to corn trypsin inhibitor, DFP also failed to diminish the ability of Factor XIIa to decrease the number of monocyte binding sites for monomeric IgG (Table II) .
We studied whether protein synthesis is required for the Bound (molecules/monocyte) x 10-3 (Fig. 3) . Monocytes (1 X 106) were preincubated with cycloheximide (10 ,ug/ml) for 40 min at 370C in a total volume of 0.5 ml before the addition of either 0.09 1AM XIIa or buffer for an additional 30 min at 370C. The monocytes were sedimented and resuspended in EDTA buffer (0.5 ml) containing 10 gg/ml ofcycloheximide for the enumeration of Fcy receptors. As noted in Fig. 3 , Factor XIIa decreased the number of IgG binding sites on monocytes preincubated with cycloheximide or buffer equally. Receptor-ligand interactions have been shown to possess specific mechanisms for the uptake and proteolytic degradation of the bound ligand within lysosomes (17) . Since chloroquine has been shown to inhibit this process involving lysosomal proteases (17), we studied the effect of chloroquine on Fig. 1 ) without altering the affinity of binding (Fig. 2) . In contrast, its precursor, Factor XII, and the low molecular weight fragment of Factor XIIa lacking most of the heavy chain region, Factor XIIf, did not reduce the number of Fcy receptors on monocytes (Fig. 1 , Table I ). Furthermore, this process did not require protein synthesis or intracellular processing, as evidenced by the experiments with cycloheximide ( Fig. 3) and chloroquine (Table I) .. Several possible mechanisms may be postulated for the reduction of Fc'yRI by Factor XIIa. The most direct would be competition of Factor XIIa for FcyRI on the monocyte. However, Factor XIIa, in contrast to a similar concentration of IgG, failed to significantly displace radiolabeled bound IgG from the monocyte surface (Fig. 4) Only Factor XIIa initiated the monocyte response, suggesting that the presence of the Factor XII heavy chain region and cleavage of the molecule are necessary conditions for the response. The light chain containing the serine catalytic region is not necessary for the response. This conclusion is evident from the data showing that neither Factor XII (Table I) nor Factor XIIf, which lacks most of the heavy chain (Fig. 1, Table   I ), affected the number of Fcy receptor sites. Furthermore, neither corn trypsin inhibitor nor DFP blocked the effect of Factor XIIa on FcyRI (Table II) . These observations raise the possibility that the heavy chain of Factor XIIa contains a domain that can interact with a distinct receptor on the monocyte, causing a downregulation or reduction in number of Fc-yRI ligand binding sites. The two domains homologous to epidermal growth factor present in the heavy chain region of Factor XIIa are candidates for this function (4, 5) . These domains may only be available after the single proteolytic cleavage that converts Factor XII (an inactive agonist) to Factor XIIa (an active agonist).
The regulation of monocyte Fcy receptor expression by Factor XIIa may be of pathophysiologic importance. Biologically active products of inflammation generated by plasma proteins can interact with circulating blood cells, including phagocytes. The interplay between these systems has been shown to be critical in inflammation, as evidenced by the action of C5a as a chemotaxin for phagocytic cells. During infection the weight of evidence suggests that Fcy receptor expression on macrophages is increased as a consequence ofbacterial products, and the release of lymphokines such as y-IFN (13, 19, 22) . Under this circumstance, Factor XIIa may serve a regulatory function in modulating Fcy receptor expression.
